NEW YORK, July 5, 2011 /PRNewswire/ — Reportlinker.com
announces that a new market research report is available in its
catalogue:
Acute Coronary Syndrome (ACS) Drug Market
http://www.reportlinker.com/p0567592/Acute-Coronary-Syndrome-ACS-Drug-Market .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
What are the commercial prospects for the pharmacological
treatment of acute coronary syndrome? Our new report shows you its
revenue potential from 2011 to 2021. We predict and explain the
commercial opportunities in that industry and market.
Our report gives you revenue forecasts to 2021 for treating
acute coronary syndrome (ACS). You will find market predictions at
total world, submarket, product and national levels. We aim to save
you time and aid your decisions through our research, analysis and
discussions.
Our study covers ACS treatments, including those for unstable
angina (UA) and acute myocardial infarction (AMI). You will see
commercial prospects for platelet aggregation inhibitors,
anticoagulant treatments, fibrinolytic agents and their subgroups
to 2021.
You will see how drugs like Plavix, Effient/Efient, ReoPro,
Integrilin, Aspirin Cardio, Lovenox, Angiomax/Angiox, Arixtra and
Metalyse/TNKase will perform to 2021. Our report provides many
revenue forecasts and discussions, giving answers you
need.
In particular, we discuss the R&D pipeline. There are
opportunities for original and generic drugs for treating acute
coronary syndrome from 2011 onwards.
We help you to assess the ACS treatment industry and market’s
strengths, weaknesses, trends and revenue opportu
‘/>”/>
SOURCE